Publication: Uso de inmunoglobulinas no específicas en el
paciente pediátrico
Loading...
Official URL
Full text at PDC
Publication Date
2018-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La utilización de inmunoglobulinas intravenosas (IgIV) ha experimentado un aumento importante en los últimos años, tanto en indicaciones autorizadas como en no autorizadas, de modo que hoy en día constituye una opción terapéutica en numerosas patologías. Objetivo: realizar un estudio de utilización para describir el perfil de uso de las IgIV en pacientes pediátricos del HGUGM. Metodología: estudio observacional, retrospectivo de revisión de historias clínicas de los pacientes pediátricos que recibieron tratamiento con IgIV desde enero de 2015 hasta octubre de 2017. Resultados: en el período de estudio se administraron IgIV a 134 pacientes pediátricos, en el 53% de los casos como tratamiento de reposición y en el 47% restante como inmunomodulador. Se identificó la utilización de IgIV en condiciones diferentes a las autorizadas en ficha técnica en 60 pacientes (45% del total). Conclusiones: el incremento del número de indicaciones no contempladas en ficha técnica para las que se utilizan las IgIV pone de manifiesto la necesidad de desarrollar y actualizar protocolos de uso que permitan definir el perfil de pacientes para los que este tratamiento suponga una opción eficaz, segura y eficiente.
The use of intravenous antibodies (IgIV) has experienced an important increase in the last years, so much in authorized indications as in not authorized, so that nowadays it constitutes a therapeutic option in numerous pathologies. Objectives: Conducting a study to describe the profile of use of the IgIV in pediatric patients in HGUGM. Methodology: observational, and retrospective study which we review clinical history about pediatric patients who received treatment with IgIV from January, 2015 until October, 2017. Results: in the study period IgIV was administered to 134 pediatric patients, being in 53 % of the cases like restoration treatment and in 47 % remaining as inmunomodulator treatment. The IgIV use was identified in different conditions to authorized in title role in 60 patients (45 % of the whole). Conclusions: the increase of the number of indications not contemplated in title role for which the IgIV is used reveals the need to develop and to update protocols of use that allow to define the patients' profile for that this treatment supposes an effective, sure and efficient option.
The use of intravenous antibodies (IgIV) has experienced an important increase in the last years, so much in authorized indications as in not authorized, so that nowadays it constitutes a therapeutic option in numerous pathologies. Objectives: Conducting a study to describe the profile of use of the IgIV in pediatric patients in HGUGM. Methodology: observational, and retrospective study which we review clinical history about pediatric patients who received treatment with IgIV from January, 2015 until October, 2017. Results: in the study period IgIV was administered to 134 pediatric patients, being in 53 % of the cases like restoration treatment and in 47 % remaining as inmunomodulator treatment. The IgIV use was identified in different conditions to authorized in title role in 60 patients (45 % of the whole). Conclusions: the increase of the number of indications not contemplated in title role for which the IgIV is used reveals the need to develop and to update protocols of use that allow to define the patients' profile for that this treatment supposes an effective, sure and efficient option.
Description
UCM subjects
Unesco subjects
2412 Inmunología, 3209 Farmacología